Piramal Pharma Share Price Today: NSE and BSE Analysis with Future Projections

Piramal Pharma Limited is a diversified international pharmaceutical company, and a central figure in the Piramal Group, and its operations spread in regulated and emerging markets. The company is involved in three primary segments namely Contract Development and Manufacturing Organisation (CDMO), Complex Hospital Generics, and Consumer Healthcare. The company as of February 2026 is also in a period of operational transition where it is trying to balance long-term growth goals with near-term profitability requirements.  This article will provide complete information about Piramal Pharma Share Price.

Piramal Pharma Ltd Company Overview

Piramal Pharma Limited is the pharmaceutical division of Piramal Group, an Indian diversified conglomerate of interests in the fields of healthcare, financial services, and real estate. The group ventured into pharmaceuticals in 1988 with the acquisition of Nicholas Laboratories which formed the basis of what will later emerge as a world wide healthcare company. Over time, Piramal Pharma has been growing aggressively by mergers, acquisitions as well as capacity build-ups, both locally in India and internationally.

One of the high points of the company’s history was achieved in 2010, when Piramal Group disposed of its local formulations unit to Abbott Laboratories in a deal worth USD 3.7 billion. This deal transformed the pharmaceutical strategy of the group giving it the opportunity to redirect capital into the global CDMO operations, complex generics, and consumer healthcare. Afterwards, Super Religare Laboratories divested in the diagnostic services making the company even more focused on major pharmaceutical manufacturing and services.

Piramal Pharma Current Price Performance

Piramal Pharma closed at ₹162.84, with an estimated market capitalization of 21,008 crore. The volumes of trading are high which shows that investors are still involved. Although the stock has increased by 6.56 percent in the last one week, it is still losing by 26.40 percent on an annual basis which is indicative of trends in the pharmaceutical sector in general. The valuation ratios seem farfetched, having a very high P/E ratio of 230.53, primarily due to the low earnings being presently suppressed.

Piramal Pharma 52-Week High and Low

In the past year, Piramal Pharma has reached maximum heights of 240.95 and minimum of 148.31. Stock is currently more aligned to the lower band indicating that the stock has technical support. Nevertheless, the volatility is still high with the beta standing at 1.30 indicating that the price movements might continue either way.

Piramal Pharma Share Price Forecasts (2026–2030)

It is estimated that recovery will take an upward trend as opposed to a spurt. In the case of 2026, it is expected to have a range of 245 to 325 owing to better inflows of CDMO orders and normalization of US biopharma funds. Optimistic scenarios take the value as high as ₹800 by 2030 and conservative projections are ₹650 since competition has not waned.

Piramal Pharma Latest Financial & Business Updates

Piramal Pharma has a net loss of 136 crore in the third quarter, in FY26 as compared to a small profit in the previous year. The revenue also dropped by 3 percent to 2,140 crore as a result of destocking. To the positive, the company had a leadership in Sevoflurane, growth in consumer health e-commerce stands at 40 percent, and the USFDA zero-observation track record was maintained, with four at Lexington site (classified as VAI).

Piramal Pharma Listing Overview

Piramal Pharma Limited did not enter the stock market the traditional way via an IPO. Rather it was registered after a demerger by Piramal Enterprises Limited. The company entered the stock market on 19 October 2022 on both the NSE and BSE. The shares were found at approximately 200 per share and the face value of the share was 10 and new shares were never issued to raise new capital.

Piramal Pharma Listing Details on NSE and BSE

In August 2022, Piramal Pharma was listed on NSE and BSE upon receiving the permission of the NCLT. The stock has a symbol PPLPHARMA in NSE, and 543635 in BSE. Piramal Pharma restructuring was an efficient tax-saving exercise because existing shareholders at Piramal enterprises were able to get 4 shares of Piramal Pharma instead of 1 share. The stock is a traded stock in the equity segment and has an ISIN INE0DK501011.

Demerger Background and Business Structure

The demerger was the long term reorganization plan of the Piramal Group to establish a concentration and separate business. The group has CDMO operations, critical care portfolio and consumer healthcare business housed in Piramal Pharma. In June 2020, The Carlyle Group purchased a 20-percent stake in the pharma business and the process started. The last phase of this division was the stock market listing in 2022.

Piramal Pharma Trading and Market Information

Piramal Pharma is actively traded on both NSE and BSE; there are regular volumes of trades and high rates of retail trading. The stock belongs to big indices like BSE 100, BSE 200, and S&P CNX 500 editions to its liquidity as well. The share prices are currently trading at around 162, and this is characteristic of the pharmaceutical stock which is volatile in nature. The firm in 2023 had also undertaken a minor rights issue of 18 crore at 81 per share, which was mainly to bolster its balance sheet.

Piramal Pharma Fundamental Insights

Basic screeners show that there were better book value and increased provisions. The Return on Equity is 9.83 with a low leverage ratio of 0.17 in terms of debt to equity ratio. Piramal Pharma is at a disadvantage compared to its peers such as Sun Pharma in terms of assets value but stronger in terms of earnings growth, hence it is best suited to the long term and high-risk investor.

Piramal Pharma Technical View

The trend of the technical indicators is mixed. There is INR neutrality within the 42-50 range, whereas such indicators as MACD and CCI are giving initial buy signals. The stock must decisively break over 170 to declare a bullish break out. Volatility is approximately 2.5 and it is appropriate to swing traders and dangerous to short-term investors.

Piramal Pharma Financial Performance Overview

The  financial performance of Piramal Pharma Limited during the last couple of years is that of a company that is in the transition process. Although revenues have been on the rise, the profitability has been under pressure since the interest costs are high, the depreciation experienced because of the recent capacity expansions, and the fluctuation in margins in some lines.

Revenues grew at a moderate pace on a consolidated basis with a 30-percent increment in FY21 to 9,151 crore in FY25. The performance of net profit has however been erratic with some years and quarters recording a loss caused by high expenses and exceptional items.

Piramal Pharma Margin and Profitability Trends

The operating margins have varied over the years which is a sign of variation in revenue mix, generics pricing pressure and ramp-up costs in the CDMO segment. Although the margins of CDMO are structurally higher, the profitability in the short-term has been affected as less of them are utilized in some plants and the fixed costs are increased.

The return ratios are also kept down, and ROCE is 6.45 percent and ROE is slightly more than 1 percent. These are very low compared with large-cap pharma counterparts, and it shows that the work still needs to be done in terms of long-term operating leverage increase and capital efficiency.

Piramal Pharma Balance Sheet 

The balance sheet of Piramal Pharma Limited is relatively highly leveraged as compared to most pharmaceutical counterparts. The borrowings were about 4856 crore in FY25, which is an investment in manufacturing plants, acquisitions, and international growth. A large percentage of total assets is made up of fixed assets and capital work-in-progress, and this means that the company continues to invest in capacity and infrastructure. Although these investments will stimulate growth in the long term, they have also contributed to growth in the near term in the form of depreciation and interests.

Piramal Pharma Cash Flow Analysis

The operating cash flows have been positive and this has been supported by constant revenues and working capital management. Nonetheless, cash flow investment has been moderate since capital expenditure and expansion programs are always negative. Financing cash flows have amortised over the past years, and this is an indication of a more conservative outlook of leverage.

The prospect of the company to produce sustained free cash flow will be important in enhancing balance sheet strength as well as shareholder returns in the medium term.

Piramal Pharma Pattern of Shareholding

The company has a strategic stability in promoters with a holding of around 34.85 percent. The foreign institutional investors are also important stakeholders but their shareholding has been steadily decreasing in the last few quarters. Domestic institutional investors have become more involved, which indicates the rising faith in the long-term perspectives of the company.

Future Outlook

The success of Piramal Pharma Limited CDMO strategy is directly related to the long-term perspective of this company. The growing emphasis on the integrated projects, the increased use of the international facilities and the stabilization of the situation in the complicated business of generics could contribute to the enhancement of the margins and the ratios of returns greatly. Although short-term profitability will be moderate, the technical necessity of outsourced pharmaceutical manufacturing gives a good environment towards long-term growth.

Conclusion

Piramal Pharma Limited is a well-differentiated pharmaceutical enterprise that has good global CDMO capacities and operates in regulated markets. Although the company has experienced some profitability difficulties over the past several years, its strategic resources, bundled services provider, and the long-term industry tail winds have put the company in a good position to experience slow changes. The company should be considered a long term turnaround and compounding play and not a short term earnings play.

FAQs